| Autor: |
Stoen MJ; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway. mst207@post.uit.no., Andersen S; Translational Cancer Research Group, Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway.; Department of Oncology, University Hospital of North Norway, Tromso, Norway., Rakaee M; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway.; Translational Cancer Research Group, Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway., Pedersen MI; Translational Cancer Research Group, Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway., Ingebriktsen LM; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway.; Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, 5021, Bergen, Norway., Bremnes RM; Translational Cancer Research Group, Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway.; Department of Oncology, University Hospital of North Norway, Tromso, Norway., Donnem T; Translational Cancer Research Group, Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway.; Department of Oncology, University Hospital of North Norway, Tromso, Norway., Lombardi APG; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway., Kilvaer TK; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway.; Department of Oncology, University Hospital of North Norway, Tromso, Norway., Busund LT; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway.; Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway., Richardsen E; Translational Cancer Research Group, Institute of Medical Biology, UiT the Arctic University of Norway, 9037, Tromso, Norway.; Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway. |
| Abstrakt: |
MicroRNAs (miRs) are small non-coding RNA molecules, which are involved in the development of various malignancies, including prostate cancer (PCa). miR-17-5p is considered the most prominent member of the miR-17-92 cluster, with an essential regulatory function of fundamental cellular processes. In many malignancies, up-regulation of miR-17-5p is associated with worse outcome. In PCa, miR-17-5p has been reported to increase cell proliferation and the risk of metastasis. In this study, prostatectomy specimens from 535 patients were collected. Tissue microarrays were constructed and in situ hybridization was performed, followed by scoring of miR-17-5p expression on different tumor compartments. High expression of miR-17-5p in tumor epithelium was associated with biochemical failure (BF, p < 0.001) and clinical failure (CF, p = 0.019). In multivariate analyses, high miR-17-5p expression in tumor epithelial cells was an independent negative prognostic factor for BF (HR 1.87, 95% CI 1.32-2.67, p < 0.001). In vitro analyses confirmed association between overexpression of miR-17-5p and proliferation, migration and invasion in prostate cancer cell lines (PC3 and DU145). In conclusion, our study suggests that a high cancer cell expression of miR-17-5p was an independent negative prognostic factor in PCa. |
